

SOUTH DAKOTA BOARD OF REGENTS

ACADEMIC AFFAIRS FORMS

New Course Request

	Pharmacy & Allied Health Professions/Pharmaceutical Sciences		
SDSU			
Institution	Division/Department		
Dennis D. Hedge		2/7/2018	
Institutional Approval Signature		Date	

Section 1. Course Title and Description

Prefix & No.	Course Title	Credits
PHA 353	Pathophysiology, Pharmacology & Toxicology II	3

^{*}short title for use in Colleague: Pathophys, Pharmacol, Tox II

Course Description

Continuation of Pathophysiology, Pharmacology & Toxicology I. Pathophysiology of common and significant diseases, the pharmacology of medications used in treatment of those diseases, and basic principles of prevention and treatment of drug overdoses and other poisonings.

Pre-requisites or Co-requisites

Prefix & No.	Course Title	Pre-Req/Co-Req?
PHA 352	Pathophysiology, Pharmacology & Toxicology I	Pre-Req

Registration Restrictions

None

SDSU Catalog Note: P1 year standing.

Section 2. Review of Course

2.1. Was the course first offered as an experimental course?

 \boxtimes Yes (if yes, provide the course information below) \square No

2.2. Will this be a unique or common course?

☑ Unique Course

Prefix & No.	Course Title	Credits
PHA 320/ NURS 323	Introduction to Pathophysiology	3
NURS 321	Pharmacology	3

Provide explanation of differences between proposed course and existing system catalog courses below:

Pathophysiology content is covered in PHA 320/NURS 323 Introduction to Pathophysiology. The proposed new course is an integrated course including pathophysiology, pharmacology, and toxicology. The integrated nature of the course distinguishes the proposed class from NURS 323. PHA 320 will be deleted due to the introduction of the integrated course. The intent of the integration is to allow greater depth of content coverage and improved student learning. There is a pharmacology course for nursing students (NURS 321) in the inventory. This course is focused on nursing applications related to drug administration, is only a one-semester three-credit course, and is not integrated. Therefore, it does not have the required breadth and depth of pharmacology content required for the Doctor of Pharmacy program. The proposed Pathophysiology, Pharmacology, and Toxicology course sequence is an overall four-semester course sequence with a fully integrated design that distinguishes it from NURS 321.

☐ Cor	☐ Common Course Indicate universities that are proposing this common course:					
	\square BHSU	\square DSU	\square NSU	\square SDSMT	\square SDSU	\square USD
Section	on 3. Other (Course I	<u>nformation</u>			
3.1.	Are there inst	tructional	staffing impacts?			
⊠ No.	Replacement of	of P	HA 442 Pharmacol	logy I, 5 cr		
	-	(0	course prefix, cours	e number, name	e of course, cre	edits)
		E	affective date of del	etion: 8/15/2	2019	
This co	ourse involves t	he integra	tion of content fron	n multiple separ	ate courses. T	The same faculty
involv	_		ly separate courses		-	
3.2.			which course will	be offered: Pha	armaceutical S	Sciences (B.S.)/
	acy (Pharm.D.)					
3.3.	-		method by univer	•		
3.4.	-	•	hod by university:	001 – Face to f	face, Term bas	sed
3.5.			fective: Fall 2018	21 1:49		
3.6.		_	e course for additi			
	 ☐ Yes, total credit limit: ☑ No 3.7. Will grade for this course be limited to S/U (pass/fail)? 					
3.7.	O	r unis coul	rse be illilited to S	(U (pass/lan):		
	⊠ No		t h a commad 2			
	Will section e					
	, max per section				6 J	
3.9.			(i.e., be considere			
	with any other unique or common courses in the common course system database in Colleague and the Course Inventory Report?					
	_	ourse my	entory Keport.			
	☐ Yes ⋈ No3.10. Is this prefix approved for your university?					
	_	арргочси	ioi your universit			
	 ⊠ Yes □ No Section 4. Department and Course Codes (Completed by University Academic 					
		ment an	u Course Coues	<u>(Completeu</u>	by Univers	Sity Academic
Affai		mautman	Codo, CDAIID			
4.1. University Department Code: SPAHP						
4.2. Proposed CIP Code: 51.2001						
Is this a new CIP code for the university? ☐ Yes ☒ No NEW COURSE REQUEST						
Supporting Justification for On-Campus Review						
supporting desimilation on campus metron						
Teresa Se	efeldt		Teresa Seefeldt			9/25/2017
_	Originator		Signature			Date
Om Perur			Om Perumal			10/30/2017
	ent Chair		Signature			Date
Jane Mort			Jane Mort			11/16/2017
School/C	School/College Dean		Signature			Date

1. Provide specific reasons for the proposal of this course and explain how the changes enhance the curriculum.

The proposed course involves integration of content from four existing courses (PHA 320 Introduction to Pathophysiology, PHA 442 Pharmacology I, PHA 443 Pharmacology II, and PHA 444 Toxicology). The content from these courses is highly interrelated as understanding of the pathophysiology of disease is critical to understanding how drugs work to treat that disease and knowledge of pharmacology is critical to understanding the effects of poisonings and overdoses.

By integrating the content into one course series, students should be better able to make the connections between the content areas with the goal of improving understanding and retention. In addition, new student learning outcomes and expectations for pharmacy practice require a greater depth of knowledge in pathophysiology. Specifically, student pharmacists need to understand detailed mechanisms of disease processes to understand how the medications impact these mechanisms. Integration of the pathophysiology content with pharmacology and toxicology will allow for greater depth of coverage and help students make the connections between disease and drug mechanism of action. 2. Note whether this course is: \times Required

Elective 3. In addition to the major/program in which this course is offered, what other majors/programs will be affected by this course? Currently, pathophysiology is offered as a joint course between nursing and pharmacy. With this change, the pharmacy students will take the integrated pathophysiology, pharmacology, and toxicology course series instead of the stand-alone pathophysiology course. 4. If this will be a dual listed course, indicate how the distinction between the two levels will be made. NA 5. Desired section size 80 6. Provide qualifications of faculty who will teach this course. List name(s), rank(s), and degree(s). Gudiseva Chandrasekher, PhD, Associate Professor of Pharmaceutical Sciences Shafiqur Rahman, PhD, Professor of Pharmaceutical Sciences Teresa Seefeldt, PharmD, PhD, Associate Professor of Pharmaceutical Sciences 7. Note whether adequate facilities are available and list any special equipment needed for the course. Adequate classroom facilities are available to teach this course. No special equipment is needed. 8. Note whether adequate library and media support are available for the course. Library and media support resources are adequate for this course. No special resources are needed. 9. Will the new course duplicate courses currently being offered on this campus? □ Yes П No 10. If this course may be offered for variable credit, explain how the amount of credit at each offering is to be determined. NA